JDRF Blog

This month, we wanted to recognize some of our amazing monthly donors and thank them for their support. Their stories will help you understand why they’re In to End Diabetes.

Your stories make all the difference.

Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for over two years—the onset of type 1 diabetes (T1D) in participants with a high risk of developing the disease. This was the first ever study in humans to show a delay in the onset of T1D. But it doesn’t stop there. JDRF has very promising updated results.

The type 1 diabetes (T1D) community has always embraced new technology – with insulin pumps, continuous glucose monitors (CGMs), flash glucose monitors (FGMs), and a variety of T1D-focused apps rapidly becoming essential tools for many people. It’s no surprise, then, that the T1D community has quickly adapted to accessing healthcare virtually.

My name is Rebecca Redmond, and I am #MoreThanT1D.

I’m a writer, a public speaker, a mom, a wife, a sister, a daughter, a friend…and Sir Frederick Banting’s cousin.

If you haven’t yet heard, you’ve been invited to Canada’s largest virtual house party turning type one diabetes into type none…the JDRF House ParT1D for a Cure, presented by Omnipod!

We are sharing information that addresses some of the top concerns of the T1D community. Note these responses are not intended to be medical advice, for that—as always—you must consult your own healthcare team.

TrialNet—an international JDRF-supported network of leading academic institutions, endocrinologists, physicians, scientists and healthcare teams dedicated to finding cures for type 1 diabetes (T1D)—has a new in-home test kit that makes screening far easier and more convenient and at no cost to you!

When Sarah Ayers and her boyfriend returned from a trip to Europe in early March, talk of an impending pandemic in Canada was flooding the media and travelers were being advised to self-isolate as a precaution

A Q & A with Dr. Farid Mahmud, JDRF-funded pediatric endocrinologist at The Hospital for Sick Children in Toronto.

Knowing that many research institutes are closed or have temporarily diverted staff or resources to the COVID-19 pandemic, we are now asking the question: What does this mean for T1D research?

A Q & A with Dr. Rémi Rabasa-Lhoret, JDRF-funded clinical scientist and endocrinologist at the Institut de recherches cliniques de Montréal